Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GUMPTION: Guided Treatment Based on Mini-PDX in Metastatic Refractory Triple Negative Breast Cancer
NCT04745975Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Feb 2021
- Primary completion
- Jan 2023
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in triple-negative breast cancer (TNBC) (2 arms), sponsored by Fudan University. Primary endpoint: Objective Response Rate at 1 year. Status: unknown.
02
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04745975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04745975.